LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-28. Numbers and descriptions here follow the published literature rather than marketing material.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
=== Recent === Flat-screen display technology began in the 2000s, replacing the cathode-ray tube displays of the previous century. In the years that followed, technology evolved and displays became increasingly thinner, higher in resolution and larger. As a result, the required composite structures become increasingly complex, and the manufacturing methods became more demanding. Edwards Vacuum is involved in flat-screen display production with its turbomolecular pumps, which enable the high levels of vacuum required for the production process and coating of these displays. Abatement installations remove global warming, toxic, pyrophoric, and corrosive gases in a safe, regulatory way. Vacuum coating is used in other industries, including solar cell photovoltaics. They are produced with processes such as crystalline silicon, CdTe, CIGS, or Silicon Thin Film Technology, all of which require vacuum. Lithium-ion batteries are a rapidly growing market, that also requires large amounts of vacuum in various stages of their production. Edwards CTI-Cryogenics and Edwards Polycold cryopumps and cryochillers play their role in cryogenic fields: MRI machines that uses liquid helium and require cryogenic cooling, storage of large quantities of food, freezing of blood and tissues samples, and semiconductors, as their technology and structures become more complex.
== June 11, 1915 (Friday) == Second Battle of Artois — Despite the Germans inflicting major casualties, French advanced 500 metres (550 yd) on a 300-metre (330 yd) front towards Neuville-Saint-Vaast, France. Battle of Hébuterne — The German launched the first of two counterattacks, with the first failing to dislodge the French. Second Battle of Garua — British and French forces formally took control of all garrisons around Garua, German Cameroon. Friar Leonard Melki and hundreds of other Christians are driven out of Mardin and massacred by Ottoman troops. Born: Magda Gabor, Hungarian actress, eldest sister of the Gabor sisters which included Eva and Zsa Zsa; as Magdolna Gábor, in Budapest, Austria-Hungary (present-day Hungary) (d. 1997)
=== Aurore Adekunle === Aurore Adekunle (Faith Alabi) is a Tory MP. She is introduced in series 2 as an ally of Anna Gearing, joining her on a duck shoot in Wales hosted by Pierpoint for investors in healthcare startup Rican. Gus strikes up a friendship with Aurore at the shoot, and she hires him to work at her government office to help handle her mounting meetings with constituents. Gus later leaks to Harper that the government is allowing Amazon to acquire drugstore chain FastAide, jeopardizing Jesse's planned short of the company; Harper tells Jesse, who criticizes the acquisition on live TV, thereby reviving the government inquiry—boosting Aurore's reputation—while saving his own short. Aurore, however, is forced to fire Gus after he lets slip that he was the source of the leak, even though the information ended up helping her. Aurore reappears in series 3, having been promoted to Energy Secretary; she publicly champions Henry Muck's green-energy startup Lumi, while privately scheming with Henry's uncle Lord Norton and godfather Otto Mostyn to elevate her own position in government. Aurore publicly takes responsibility for Lumi's collapse during a government inquest, thereby positioning her for a future bid for Prime Minister. She and Norton later capitalize on the news of Barclays' failed acquisition of Pierpoint, framing it in the news as an antitrust win for Aurore. Aurore does not appear in series 4, with Lord Norton describing her as "hated" by the Conservative Party and was targeted by the 1922 Committee.
Sources: en.wikipedia.org
March 26: Residents in France, regardless of nationality, are subject to personal tax if they enjoy their rights. For women, this applies to single women with a profession or personal income living independently, women separated from their husbands, and widows. April 19: For a man to be a voter, his and his wife's assets are considered in calculating contributions. If a woman is separated, divorced, or widowed, her contributions are associated with a close male relative's assets (excluding illegitimate children) at her discretion. 1832
Local flaps are created by freeing a layer of tissue and then stretching the freed layer to fill a defect. This is the least complex type of flap and includes advancement flaps, rotation flaps, and transposition flaps, from least to most complex respectively. With an advancement flap, incisions are extended out parallel from the wound, creating a rectangle with one edge remaining intact. This rectangle is freed from the deeper tissues and then stretched (or advanced) forward to cover the wound. The flap is disconnected from the body, except for the uncut edge which contains the blood supply which feeds in horizontally. A rotation flap is similar except that, instead of being stretched in a straight line, the flap is stretched in an arc. The more complex transposition flap involves rotating an adjacent piece of tissue, resulting in the creation of a new defect that must then be closed. Regional or interpolation flaps are not immediately adjacent to the defect. Instead, the freed tissue "island" is moved over or underneath normal tissue to reach the defect to be filled, with the blood supply still connected to the donor site via a pedicle. The pedicle can be removed after a new blood supply has formed. Examples: pectoralis major myocutaneous flap and deltopectoral flap for head and neck defects, and latissimus dorsi flap and traverse rectus abdominal muscle (TRAM) flap for breast reconstruction. Distant flaps are used when the donor site is far from the defect. These are the most complex class of flap.
New drugs are the products of a long drug development process, the first step of which is often the discovery of a new enzyme inhibitor. There are two principle approaches of discovering these inhibitors. The first general method is rational drug design based on mimicking the transition state of the chemical reaction catalysed by the enzyme. The designed inhibitor often closely resembles the substrate, except that the portion of the substrate that undergoes chemical reaction is replaced by a chemically stable functional group that resembles the transition state. Since the enzyme has evolved to stabilise the transition state, transition state analogues generally possess higher affinity for the enzyme compared to the substrate, and therefore are effective inhibitors. The second way of discovering new enzyme inhibitors is high-throughput screening of large libraries of structurally diverse compounds to identify hit molecules that bind to the enzyme. This method has been extended to include virtual screening of databases of diverse molecules using computers, which are then followed by experimental confirmation of binding of the virtual screening hits. Complementary approaches that can provide new starting points for inhibitors include fragment-based lead discovery and DNA Encoded Chemical Libraries (DEL). Hits from any of the above approaches can be optimised to high affinity binders that efficiently inhibit the enzyme.
(Sponsored by The Association of Schools of Public Health (ASPH). Eaton DL & Cui J. (2023) "Biotransformation of Xenobiotics ", in Patty's Industrial Hygiene and Toxicology, 7th Edition, Ed. D. Paustenbach, J. Klaunig, L. Levy & H. Greim, Wiley Press. e91320 Eaton, DL, *Vandivort, TC & Gallagher, EP. (2025). Introduction to the Principles of Toxicology, In: Comprehensive Toxicology, C. McQueen, Editor, Elsevier Sciences, Vol. 1, General Principles, 4 th, Edition, Chap. 1, 2025. Eaton, D. L., Goldstein, B. D. & Henifin, M. S. (2025). Reference Guide on Toxicology. In Reference Manual on Scientific Evidence (4th ed., pp. 1027-1104–686). National Academies Press / Federal Judicial Center.
Sources: en.wikipedia.org
=== First "scientific" syntheses: aniline dyes 1858 – 1870 === In the mid 19th century, the coal tar industry, particularly in England, produced the precursors needed for a large amount of organic syntheses, in large quantities. For the first eight years after the first marketable synthetic dye, Mauveine, until the middle of the 1860s, British and French firms were the major dye producers. The second half of the 1860s saw German dye works surpassing their competition in both capacity and market share. During 1870, German firms were responsible for roughly half of the world's production of dyes and pigments. Aniline dyes were produced at scale, in part because of many advances in the synthesis of their precursors. Antoine Bechamp described a process for reducing nitrobenzene to aniline in 1854, known as the Bechamp Process, making the production of aniline easy. Widespread isolation of phenol from coal tar, made its nitration more economical, generally the path of the synthesis flowed: coal tar → nitrobenzene → aniline → dyes. According to Henry Perkin himself "This industry holds an [sic] unique position in the history of chemical industries, as it was entirely the outcome of scientific research."
=== Class III === Class III fusion proteins are distinct from I and II. They typically consist of five structural domains, where domains 1, 2 and 4 often contain more β-sheets and domains 3 and 5 are richer in α-helices (defining domain 1 as being closer to the N-terminus and 5 closer to the C-terminus). In the pre-fusion state, the domains nest, with domain 1 protected by domain 2, which is nested in domain 3, which is protected by domain 4. Domain 1 contains a bipartite site, likely for membrane fusion, within the loops connecting its long beta strands, and domain 5 serves as a linker between domain 4 and the C-terminal membrane-proximal and transmembrane domains. Domain 3 refolds upon fusion, while domain 5 loses its alpha helical structure.
== Adverse effects == Adverse effects include reactions at the injection site, such as a hot or painful feeling as well as general reactions such as nausea and vomiting. All of these are usually mild and transient. Allergy-like effects such as itching, sneezing, coughing and yawning can be the first sign of severe adverse reactions, especially a shock. Accidental intrathecal administration (into the spinal canal) can result in life-threatening reactions such as convulsions, cerebral (brain) edema or cerebral bleed.
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.